FridaySep 05, 2025 10:00 am

NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers

The NCI, or National Cancer Institute, a federal body, has revealed that it will no longer fund a program that has been running for 26 years focused on advancing clinical studies on children with brain cancers.  The group, Pediatric Brain Tumor Consortium, was founded in 1999 to bring together 15 academic institutions and pediatric hospitals within the United States and Canada to conduct early-stage clinical trials (Phase 1 and Phase 2). This consortium has a record of conducting trials aimed at exploring new therapies, strategies for delivering radiation treatment, and finding new technologies to deliver treatments specifically focused on pediatric…

Continue Reading

ThursdaySep 04, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile. CEO notes that “the FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.” Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing. Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only…

Continue Reading

ThursdaySep 04, 2025 10:00 am

Research Uncovers Possible Way to Repair Myelin in MS Patients

According to new research published in the journal Cell, targeting the SOX6 protein could open a new way to repair myelin in individuals afflicted by multiple sclerosis. According to the researchers, this SOX6 protein regulates the maturation of cells referred to as oligodendrocytes which manufacture myelin.  The team found that when SOX6 is overactive, as is the case in MS patients, oligodendrocytes remain immature and can’t therefore produce myelin. By targeting SOX6, the researchers believe that myelin production can resume and consequently some form of restoration in function could be achieved in patients. In healthy people, SOX6 is less active,…

Continue Reading

WednesdaySep 03, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’

The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors. A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle(TM). A strategic partnership with Shanghai Medicilon supports rapid IND filings for up to 20 drug candidates, significantly accelerating development timelines. Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency. The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile…

Continue Reading

TuesdaySep 02, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Building Market Awareness Through Strategic Education Platform

BreastCT.com launches as a comprehensive educational resource focused on dedicated breast CT technology and IzoView's clinical advantages for dense breast tissue imaging Platform designed to evolve alongside company progression through clinical studies, regulatory phases, and commercial launch milestones Strategic positioning within successful imaging category creation context provides clear market reference framework for IzoView's commercial potential The Pre-Commercial Challenge: Educating Markets on Breakthrough Technology Medical device companies developing breakthrough technologies face a fundamental commercialization challenge beyond regulatory approval: market education. When innovations represent genuine advances over existing standards of care, successful adoption requires comprehensive stakeholder education across patients, clinicians, and healthcare…

Continue Reading

TuesdaySep 02, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically significant reductions in suicidal ideation with IV ketamine versus placebo and comparators. Fast Track status makes NRX-100 eligible for Accelerated Approval and the Commissioner's National Priority Voucher program. NRx is preparing an expanded access policy and seeking meetings with FDA leadership to align on data submission. The U.S. suicidal depression market is estimated at more than $3 billion annually. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug…

Continue Reading

FridayAug 29, 2025 10:00 am

Health Care Titans are Filing for Bankruptcy in America

All sectors have their share of bankruptcies every year, but the health care sector is experiencing these filings in a concerning way; major players are going under as the weight of financial headwinds takes a huge toll. The health care system has variously been described as being in the throes of a crisis, and companies within the system are no exception.  The yearly average for bankruptcy filings in America has been approximately 42, but a recent report authored by Gibbins Advisors says that in 2023 there were 79 such filings while 2024 had 57 bankruptcy filings. Bankruptcy filings seem to…

Continue Reading

ThursdayAug 28, 2025 10:00 am

Study Explains Why Blood Clotting is Common in IBD Patients

About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks. Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation.  The team, whose study author is Rebecca Mellema, explains that platelets in IBD patients are hyper-primed to clot at the smallest provocation. This is because the inbuilt…

Continue Reading

WednesdayAug 27, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology

Growing clinical evidence supports the expanding role of mobile and home-based ECG capture in improving patient outcomes. HeartBeam’s proprietary system offers a cable-free design that allows for high-fidelity ECG measurements without the complexity of conventional equipment. Portable, credit card-sized design enables patients to record symptoms at home or wherever they are. Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct…

Continue Reading

TuesdayAug 26, 2025 12:00 pm

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch

The company's rebranding reflects Izotropic's refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem Izotropic's strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 (ibn.fm/tRIr4), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000